Literature DB >> 11578777

Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice.

R B DeMattos1, R P Brendza, J E Heuser, M Kierson, J R Cirrito, J Fryer, P M Sullivan, A M Fagan, X Han, D M Holtzman.   

Abstract

The varepsilon4 allele of apolipoprotein E (apoE) is a genetic risk factor for Alzheimer's disease (AD). In order to gain a better understanding of the molecular mechanisms by which apoE and possibly other apolipoproteins produced in the central nervous system (CNS) influence AD pathogenesis, we have purified and characterized the two most abundant apolipoproteins produced in the CNS, apoE and apoJ. We purified apoE and apoJ from primary cultures of mouse astrocytes, which were derived from transgenic mice expressing human apoE isoforms in the absence of mouse apoE. Utilizing antibody affinity columns, we were able to purify both human apoE3 and apoE4, as well as mouse apoJ-containing lipoproteins. Astrocyte-secreted human apoE was present in high density-like lipoproteins of three predominant sizes ranging from 8 to 15 nm in diameter. Mouse apoJ was in particles between 10 and 17 nm in diameter with a peak size range of approximately 11 nm. ApoE and apoJ were in distinct lipoproteins. Utilization of quick-freeze, deep-etch electron microscopy revealed the apoE particles were discs while the apoJ particles were smaller and more irregular in appearance. The lipid composition of apoE particles was very different from those containing apoJ. ApoE-particles contained a similar mass of apoE and lipid, with cholesterol and phospholipid being about equal in mass per particle. ApoJ-particles were relatively lipid poor (three parts protein, one part lipid), with phospholipids being much more abundant than cholesterol. Detailed characterization of phospholipid composition by electrospray ionization mass spectrometry analysis revealed ethanolamine glycerophospholipids to be the most abundant phospholipid present in both apoE and apoJ particles. Analysis of cerebrospinal fluid from apoE3 and apoE4 transgenic mice revealed that human and mouse apoE were in particles the same size as those secreted by astrocytes. Further use of physiological preparations of CNS-derived lipoproteins may allow for a detailed understanding of the role of these molecules in the normal brain and in diseases such as AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578777     DOI: 10.1016/s0197-0186(01)00049-3

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  66 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption.

Authors:  Justin Legleiter; John D Fryer; David M Holtzman; Andtomasz Kowalewski
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

Review 3.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

Review 4.  Intra- and intercellular trafficking in sphingolipid metabolism in myelination.

Authors:  Binks W Wattenberg
Journal:  Adv Biol Regul       Date:  2018-11-23

5.  ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions.

Authors:  Philip B Verghese; Joseph M Castellano; Kanchan Garai; Yinong Wang; Hong Jiang; Aarti Shah; Guojun Bu; Carl Frieden; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

6.  LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice.

Authors:  Sophie Stukas; Lita Freeman; Michael Lee; Anna Wilkinson; Alice Ossoli; Boris Vaisman; Stephen Demosky; Jeniffer Chan; Veronica Hirsch-Reinshagen; Alan T Remaley; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2014-06-20       Impact factor: 5.922

Review 7.  Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics.

Authors:  Xianlin Han
Journal:  J Neurochem       Date:  2007-11       Impact factor: 5.372

8.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 9.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

10.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Mark A O'dell; Maia Parsadanian; Jennie W Taylor; Judith A K Harmony; Kelly R Bales; Steven M Paul; Bruce J Aronow; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.